High levels of CD34 +CD38 low/-CD123 + blasts are predictive of an adverse outcome in acute myeloid leukemia: A groupe ouest-est des leucémies aiguës et maladies du sang (GOELAMS) study

Haematologica

Volumn 96, Issue 12, 2011, Pages 1792-1798

  Vergez, François ^a,b   Green, Alexa S ^c   Tamburini, Jerome ^c,f   Sarry, Jean Emmanuel ^a   Gaillard, Baptiste ^g   Cornillet Lefebvre, Pascale ^g   Pannetier, Melanie ^c   Neyret, Aymeric ^c   Chapuis, Nicolas ^c   Ifrah, Norbert ^h   Dreyfus, François ^c,f   Manenti, Stéphane ^a   Demur, Cecile ^a,b   Delabesse, Eric ^a,b   Lacombe, Catherine ^c,f   Mayeux, Patrick ^c   Bouscary, Didier ^c,f   Recher, Christian ^a,d,e   Bardet, Valerie ^c,f  

^a CANCER RESEARCH CENTER OF TOULOUSE   (France)

^b Laboratoire d'Hematologie   (France)

^c INSTITUT COCHIN   (France)

^d UNIVERSITÉ PAUL SABATIER   (France)

^e CHU PURPAN   (France)

^f Service d'Hématologie ^*  (France)

^g SERVICE DE DERMATOLOGIE   (France)

^h ANGERS UNIVERSITY HOSPITAL   (France)

Author keywords

Acute myeloid leukemia; CD34spi +CD38 low CD123 blasts; Leukemic stem cells; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; CD123 ANTIGEN; CD34 ANTIGEN; CD38 ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLAST CELL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; KARYOTYPE; LEUKEMIA CELL; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PHENOTYPE; PREDICTION; PROGNOSIS; RETROSPECTIVE STUDY;

ADULT; AGED; ANTIGENS, CD34; ANTIGENS, CD38; ANTIGENS, NEOPLASM; BLAST CRISIS; FEMALE; HUMANS; INTERLEUKIN-3 RECEPTOR ALPHA SUBUNIT; LEUKEMIA, MYELOID, ACUTE; LEUKOCYTE COUNT; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PROGNOSIS;

EID: 82855177875     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.047894     Document Type: Article

References (28)

1. Steffen B, Muller-Tidow C, Schwable J, Berdel WE, Serve H. The molecular pathogenesis of acute myeloid leukemia. Crit Rev Oncol Hematol. 2005;56(2):195-221.
2. Dick JE. Acute myeloid leukemia stem cells. Ann NY Acad Sci. 2005;1044:1-5.
3. Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med. 2009;361(13): 1249-59.
4. Deschler B, Lubbert M. Acute myeloid leukemia: epidemiology and etiology. Cancer. 2006;107(9):2099-107.
5. Schlenk RF, Dohner K, Krauter J, Frohling S, Corbacioglu A, Bullinger L, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008;358(18):1909-18.
6. Zhi L, Wang M, Rao Q, Yu F, Mi Y, Wang J. Enrichment of N-Cadherin and Tie2-bearing CD34+/CD38-/CD123+ leukemic stem cells by chemotherapy-resistance. Cancer Lett. 2010;296(1):65-73.
7. Lane SW, Scadden DT, Gilliland DG. The leukemic stem cell niche: current concepts and therapeutic opportunities. Blood. 2009;114(6):1150-7.
8. Guan Y, Gerhard B, Hogge DE. Detection, isolation, and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML). Blood. 2003;101(8):3142-9.
9. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994;367(6464):645-8.
10. Taussig DC, Miraki-Moud F, Anjos-Afonso F, Pearce DJ, Allen K, Ridler C, et al. Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. Blood. 2008;112(3):568-75.
11. Taussig DC, Vargaftig J, Miraki-Moud F, Griessinger E, Sharrock K, Luke T, et al. Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction. Blood. 2010;115(10):1976-84.
12. Martelli MP, Pettirossi V, Thiede C, Bonifacio E, Mezzasoma F, Cecchini D, et al. CD34+ cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice. Blood. 2010; 116(19):3907-22.
13. Sarry JE, Murphy K, Perry R, Sanchez PV, Secreto A, Keefer C, et al. Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rgammac-deficient mice. J Clin Invest. 2011;121(1):384-95.
14. Jordan CT, Upchurch D, Szilvassy SJ, Guzman ML, Howard DS, Pettigrew AL, et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia. 2000; 14(10):1777-84.
15. Ishikawa F, Yoshida S, Saito Y, Hijikata A, Kitamura H, Tanaka S, et al. Chemo - therapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol. 2007;25(11):1315-21.
16. Ebinger M, Witte KE, Ahlers J, Schafer I, Andre M, Kerst G, et al. High frequency of immature cells at diagnosis predicts high minimal residual disease level in childhood acute lymphoblastic leukemia. Leuk Res. 2010;34(9):1139-42.
17. van Rhenen A, Feller N, Kelder A, Westra AH, Rombouts E, Zweegman S, et al. High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin Cancer Res. 2005;11(18):6520-7.
18. Witte KE, Ahlers J, Schafer I, Andre M, Kerst G, Scheel-Walter HG, et al. High proportion of leukemic stem cells at diagnosis is correlated with unfavorable prognosis in childhood acute myeloid leukemia. Pediatr Hematol Oncol. 2011;28(2):91-9.
19. Chevallier P, Prebet T, Pigneux A, Hunault M, Delaunay J, Perry F, et al. Influence of NPM1 and FLT3-ITD status on outcome in relapsed/refractory AML patients receiving salvage therapy including gemtuzumab ozogamicin. Leukemia. 2010;24(2):467-9.
20. van der Pol MA, Feller N, Roseboom M, Moshaver B, Westra G, Broxterman HJ, et al. Assessment of the normal or leukemic nature of CD34+ cells in acute myeloid leukemia with low percentages of CD34 cells. Haematologica. 2003;88(9):983-93.
21. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21 (24):4642-9.
22. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood. 2000;96 (13):4075-83.
23. Stone RM. Prognostic factors in AML in relation to abnormal karyotype. Best Pract Res Clin Haematol. 2009;22(4):523-8.
24. Guzman ML, Neering SJ, Upchurch D, Grimes B, Howard DS, Rizzieri DA, et al. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood. 2001;98(8): 2301-7.
25. Kern W, Bacher U, Haferlach C, Schnittger S, Haferlach T. The role of multiparameter flow cytometry for disease monitoring in AML. Best Pract Res Clin Haematol. 2010;23(3):379-90.
26. Jin L, Lee EM, Ramshaw HS, Busfield SJ, Peoppl AG, Wilkinson L, et al. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell stem cell. 2009;5(1):31-42.
27. Kugler M, Stein C, Kellner C, Mentz K, Saul D, Schwenkert M, et al. A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting. Br J Haematol. 2010;150(5):574-86.
28. Stein C, Kellner C, Kugler M, Reiff N, Mentz K, Schwenkert M, et al. Novel conjugates of single-chain Fv antibody fragments specific for stem cell antigen CD123 mediate potent death of acute myeloid leukaemia cells. Br J Haematol. 2010; 148(6):879-89.